Abstract. Recent studies have revealed a pivotal role of microRNAs (miRs) in regulating the initiation and development of multiple types of cancer. In the present study, it was discovered that miR-382 may be an important tumor suppressor in non-small cell lung cancer (NSCLC). It was demonstrated that miR-382 expression was downregulated in tumor tissues from patients with NSCLC compared with adjacent normal tissues. Furthermore, overexpression of miR-382 suppressed cell proliferation and cell migration of NSCLC cells. In addition, reverse transcription-quantitative polymerase chain reaction and the luciferase reporter assay revealed that LIM-only protein 3 (LMO3), an oncogene, acted as a direct target gene of miR-382. Notably, overexpression of miR-382 did not alter cell proliferation or migration in LMO3-silenced A549 cells. Furthermore, analysis of patient tissues indicated an elevation of LMO3 expression in tumor tissues compared with adjacent normal tissues and a negative association between miR-382 and LMO3 mRNA expression levels. Taken together, the present findings indicated that miR-382 inhibited NSCLC cell proliferation and metastasis by targeting LMO3, suggesting a tumor suppressor role of miR-382 in NSCLC.
Introduction
Lung cancer is the leading cause of cancer-associated mortality in both men and women worldwide, and >80% of lung cancer cases are diagnosed as non-small cell lung cancer (NSCLC) (1) . Although great achievements have been made in improving NSCLC diagnosis and therapeutic approaches, including the development of targeted therapies, the overall survival rate remains very low (with a 5-year survival rate of ~15%), which is accompanied with a high recurrence rate (2) .
Thus, it is of importance to uncover the molecular mechanism of cancer cell proliferation and metastasis in NSCLC to facilitate the development of novel drugs.
microRNAs (miRNAs or miRs) are small, non-coding RNAs that function by binding to the 3'untranslated regions (3'UTRs) of target mRNAs to induce mRNA degradation or suppression of transcription (3) . miRNAs have been reported to be associated with cancer development via targeting oncogenes or tumor suppressors in various cancer types, including NSCLC (4-7). However, the role of miR-382 in NSCLC development remains to be fully elucidated.
LIM-only protein 3 (LMO3) was initially discovered based on the sequence homology with LMO1 (8) . As a member of the LMO family, LMO3 is an important regulator of cell growth and differentiation during embryonic development (9) . Later research revealed that LMO3 acts as an oncogene through interacting with nescient helix-loop-helix 2 in neuroblastoma (10) . In NSCLC, LMO3 was previously reported to promote cancer cell proliferation and metastasis, and was negatively regulated by miR-630 (11) .
In the present study, a decrease in miR-382 expression was observed in the tumor tissues of patients with NSCLC compared with adjacent normal tissues. Additionally, overexpression of miR-382 significantly inhibited NSCLC cell growth and migration. Furthermore, elevated miR-382 expression decreased LMO3 mRNA and protein expression levels. The luciferase assay confirmed that LMO3 was a direct target of miR-382. More importantly, in LMO3-silenced A549 cells, miR-382 mimics did not exhibit anti-cancer effects. A negative association was also identified between LMO3 and miR-382 expression in tumor tissues from patients with NSCLC. Taken together, the present findings demonstrated a tumor suppressor role of miR-382 in NSCLC. Plasmid construction. The LMO3 3'UTR was amplified from the cDNA of A549 cells using PrimeSTAR ® Max DNA Polymerase (Takara Bio, Inc., Otsu, Japan) and cloned into pGL3 plasmids (Invitrogen; Thermo Fisher Scientific, Inc.) to construct pGL3-LMO3 3'UTR-wild type (WT). The LMO3 primer sequences were as follows: Forward: 5'-GCT CTA GAA ACA CTT TAA GTT TGA TGT G-3'; Reverse: 5'-GCT CTA GAT AAG ATC CTG ACA ATT ATA AT-3'. The thermocycling conditions were as follows: Denaturation at 98˚C for 10 sec; annealing at 55˚C for 10 sec; elongation at 72˚C for 60 sec for 35 cycles. A549 cDNA was prepared from extracted RNA using the TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). Samples were the reverse-transcribed into cDNA using the RevertAid RT Reverse Transcription kit (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. pGL3-LMO 3'UTR-mutant (mut) was constructed using a QuikChange Site-Directed Mutagenesis kit (Agilent Technologies, Inc., Santa Clara, CA, USA), according to the manufacturer's protocol.
Materials and methods

Patient
Small interfering (si)RNA transfection. LMO3 siRNAs and control siRNA were purchased from GE Healthcare Dharmacon, Inc., Lafayette, CO, USA. Knockdown of LMO3 was achieved by transfection of LMO3-specific siRNAs into A549 cells using Lipofectamine RNAiMAX (Invitrogen; Thermo Fisher Scientific, Inc.). Briefly, 30 pmol LMO3 siRNAs or control siRNA were mixed with Lipofectamine RNAiMAX in OptiMEM (Invitrogen; Thermo Fisher Scientific, Inc.), incubated for 15 min at 37˚C and subsequently added into each well containing culture medium in 6-well or 96-well plates. Cells were cultured for a further 48 h prior to experimentation. The siRNA sequences were as follows: LMO3 siRNA1, CGU CCC UAC UCG AAU GAU G; LMO3 siRNA2, CCG UUA CAC CAA AGA GCC UC; LMO3 siRNA3, GUA GUC CGU CUG GCA AAG GA; control siRNA, UAA GGC UAU GAA GAG AUA C.
Luciferase assay. miR-382 mimics and miR-negative control (NC) mimics were synthesized and purchased from Guangzhou RiboBio Co., Ltd. (Guangzhou, China). The dual luciferase assay was performed using a Dual-Luciferase ® Reporter Assay System (Promega Corporation, Madison, WI, USA). Briefly, 293 cells were cultured in 24-well plates and cotransfected with miR-382 mimics or miR-NC mimics, pGL3-LMO3 3'UTR-WT or pGL3-LMO3 3'UTR-mut and Renilla luciferase vector using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). Following 48 h, cells were collected and the dual-luciferase activity was examined with Renilla luciferase as the internal control. The sequences were of the miRs were as follows: miR-382 mimic, 5'GAA GUU GUU CGU GGU GGA UUC G3' and miR-NC mimic, 5'CAU GUA GUA CGC GUU GAG UAC C3'.
Western blot analysis. Anti-LMO3 antibody (cat. no 517019, 1:1,000) was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) and anti-GAPDH antibody (cat. no G8795; 1:5,000) was obtained from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany). Cell lysates were prepared using radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Haimen, China). The protein concentration was determined using a Pierce BCA Protein Assay kit (Thermo Fisher Scientific, Inc.). Proteins (20 µg) were separated using 8% SDS-PAGE and transferred to polyvinylidene difluoride membranes. Membranes were subsequently blocked with 5% non-fat milk at room temperature for 1 h and incubated with the indicated primary antibodies (1:1,000) overnight at 4˚C. The next day, membranes were washed with TBS-Tween 20 and incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature (cat. no. 516102; Santa Cruz Biotechnology, Inc.; 1:10,000). Subsequently, the membranes were developed using ECL Prime Western Blotting Detection Reagents (GE Healthcare Life Sciences). Images were captured and analyzed using ImageQuant TL 7.0 (GE Healthcare Life Sciences). GAPDH served as a loading control.
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
An miRNeasy Mini Kit (Qiagen, Inc., Valencia, CA, USA) was used to extract total RNA from patient tissue and cells (BEAS-2B, 293, H1299, H23 and A549) in accordance with the manufacturer's instructions. Following this, a NanoDrop 2000 kit (Thermo Fisher Scientific, Inc.) was used to measure the concentration and quality of RNA. TransScript First-Strand cDNA Synthesis SuperMix (Beijing Transgen Biotech Co., Ltd., Beijing, China) was used to reverse transcribe RNA into cDNA following manufacturer's protocol. qPCR was performed with a CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad Laboratories, Inc., Hercules, CA, USA) using SYBR Premix Ex Taq (Takara Bio, Inc.). The thermocycling conditions were as follows: Pre-denaturation at 95˚C for 30 sec; denaturation at 95˚C for 5 sec; annealing and elongation at 60˚C for 30 sec for 40 cycles. The relative expression of genes was calculated using the 2 -ΔΔCq method (13). U6 and GAPDH were used as internal controls for miRNA and mRNA, respectively. Sequences for primers used were as follows: miR-382, forward 5'-CTG CAA TCA TTC ACG GAC AAC-3' and reverse 5'-GTG TCG TCG AGT CGG CAA TTC-3'; LMO3, forward 5'-ATG CTC TCA GTC CAG CCA GA-3' and reverse 5'-TCA GCG AAC CTG GGG TGC AT-3'; U6, forward 5'-CCT GCT TCG GCA GCA CA-3' and reverse 5'-TGG AAC GCT TCA CGA A-3'; and GAPDH, forward 5'-CCA CTC CTC CAC CTT TGA C-3' and reverse 5'-ACC CTG TTG CTG TAG CCA-3'.
Cell proliferation assay. Cell growth was measured using a Cell Counting Kit (CCK)-8 (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) according to the manufacturer's protocol. Briefly, cells were seeded in 96-well plates at 37˚C. On the following day, 10 µl CCK-8 solution was added into each well and the cells were incubated for 2 h at 37˚C. The absorbance at 450 nm was detected using a microplate reader (Bio-Rad Laboratories, Inc.). At 24, 48 and 72 h following transfection with miR-382 mimics or miR-NC mimics, the cell number was analyzed using CCK-8.
Wound-healing assay. Cell migration ability was measured using a wound-healing assay. A549 cells were cultured in 6-well plates at 37˚C. On the following day, a wound was made by introducing a scratch at the center of each well with a 10-µl pipette tip. Culture medium was replaced with fresh medium containing 1% FBS, and the A549 cells were cotransfected with miR-382 mimics or miR-NC mimics and LMO3 siRNA or control siRNA using the protocol as aforementioned in the luciferase assay. An image of the scratch was then captured. Following 40 h, a second image of the scratch was captured. Subsequently, the percentage of migratory cells was analyzed using Image Pro Plus 6 (Media Cybernetics, Inc., Rockville, MD, USA).
Statistical analysis. All statistical analyses were performed using GraphPad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA). Data are presented as the mean ± standard deviation. Differences between two groups were analyzed using Student's t-test and multiple groups were analyzed using one-way analysis of variance followed by the Newman-Keuls post hoc test. P<0.05 was considered to indicate a statistically significant difference.
Results
miR-382 expression is reduced in tumor tissues from patients with NSCLC and NSCLC cell lines.
To explore the role of miR-382 during NSCLC cancer progression, the miR-382 expression levels between tumor tissues and normal adjacent tissues from 30 patients with NSCLC were compared. RT-qPCR detected a significant decrease in miR-382 expression in tumor tissues compared with normal adjacent tissues (Fig. 1A) . In addition, significantly reduced miR-382 expression levels were observed in 3 NSCLC cell lines compared with BEAS-2B, a normal human bronchial epithelial cell line (Fig. 1B) .
miR-382 suppresses cell proliferation and migration in A549 cells.
To further investigate how miR-382 influences NSCLC cell behavior, the cell proliferation and migration abilities of A549 cells were evaluated following the overexpression of miR-382 using miR-382 mimics. Compared with the control and miR-NC mimics, miR-382 mimics significantly increased the miR-382 expression levels in A549 cells (Fig. 2A) . Notably, overexpression of miR-382 provoked an inhibitory effect on A549 cell proliferation and migration (Fig. 2B-D) , suggesting that miR-382 may suppress NSCLC cell growth and metastasis.
LMO3 is a target gene of miR-382. LMO3 has been reported to promote NSCLC growth and metastasis (11) . miRanda analysis indicated that LMO3 was a potential target gene of miR-382 (Fig. 3A) . In A549 cells, overexpression of miR-382 decreased LMO3 mRNA and protein expression levels ( Fig. 3B and C) . Subsequently, whether LMO3 was a direct target gene of miR-382 was investigated using the dual luciferase assay. The results demonstrated that miR-382 mimics significantly reduced the luciferase activity in 293 cells transfected with LMO3 3'UTR-WT compared with transfection of miR-NC mimics (Fig. 3D) . In addition, miR-382 overexpression did not alter the luciferase activity of 293 cells transfected with LMO3 3'UTR-Mut (Fig. 3D) . 
miR-382 inhibits A549 cell proliferation and migration via LMO3.
To further investigate whether miR-382 is associated with the regulation of A549 cell proliferation and migration, A549-cell proliferation and migration abilities were detected following combining miR-382 overexpression with LMO3-knockdown. In A549 cells, decreased LMO3 protein expression levels were observed following transfection with LMO3 siRNA1, LMO3 siRNA2 or LMO3 siRNA3 (Fig. 4A) . LMO3 siRNA1 exhibited the highest efficiency in regulating LMO3 protein expression levels and was therefore used for the following experiments. Results indicated that silencing LMO3 markedly reduced A549 cell proliferation ability; however, combined LMO3 knockdown and miR-382 overexpression did not significantly induce further cell growth inhibition (Fig. 4B) . Furthermore, compared with the LMO3 knockdown group, there was no significant difference in the cell migration ability in cells with combined LMO3 silencing and miR-382 overexpression (Fig. 4C and D) . These data indicated that, miR-382 did not show significant effects on the cell proliferation and cell migration of A549 cells without LMO3, suggesting that miR-382 may primarily rely on the negative regulation of LMO3 to suppress NSCLC cell growth and migration.
LMO3 is overexpressed and negatively associated with miR-382 in tumor tissues from patients with NSCLC. LMO3 expression levels in patients with NSCLC were investigated. Significant elevation of LMO3 mRNA expression levels were detected in tumor tissues compared with normal adjacent tissues in patients with NSCLC (Fig. 5A) . Additionally, via analysis of the miR-382 and LMO3 mRNA expression levels in NSCLC tumor tissues, a significant negative association between miR-382 and LMO3 mRNA expression levels was revealed (Fig. 5B) . Therefore, miR-382 may promote cancer cell growth and metastasis via targeting LMO3 in patients with NSCLC.
Expression of miR-382 and LMO3 in lung carcinoma tissues.
The fold changes of miRNA-382 and LMO3 were tested in the 30 patients in the present study (10 male and 20 female) with respect to various patient characteristics, including sex, age, tumor size, histological grade and lymph node metastasis. As presented in Table I , there was no significant difference in miRNA-382 expression according to sex (P=0.938), age (P=0.331) or histological grade (P=0.156); however, low miRNA-382 expression was significantly associated with large tumor size (P=0.006) and lymph node metastasis (P=0.027). Furthermore, there was no significant difference in LMO3 expression according to sex (p=0.418) or age (P= 0.234); however, high LMO3 expression was significantly associated with large tumor size (P=0.010), low histological grade (P=0.002) and lymph node metastasis (P=0.002).
Discussion
The expression levels of many miRNAs have previously been suggested as promising biomarkers for aiding the diagnosis, prognosis and drug-sensitivity prediction of cancer (14, 15) . In the present study, it was demonstrated that miR-382 could inhibit cell proliferation and migration in NSCLC. In addition, it was demonstrated that LMO3, an oncogene, was a direct target of miR-382. Using LMO3 siRNA, it was also demonstrated that the anti-cancer effect of miR-382 was primarily reliant on the regulation of LMO3.
Via targeting oncogenes or tumor suppressors, deregulation of miRNAs may promote or inhibit cancer initiation and development. Notably, the role of miR-382 during cancer progression is considered controversial. In a previous study, miR-382 was demonstrated to downregulate phosphatase and tensin homolog and impacted the downstream protein kinase B/mechanistic target of rapamycin signaling pathway to promote angiogenesis in MKN1 human gastric cancer cells (16) . However, another study indicated that miR-382 targeted tumor suppressor Ras-like, estrogen-regulated, growth inhibitor to activate the Ras/extracellular signal-regulated kinase signaling pathway and promoted cancer proliferation and metastasis in breast cancer (17) . In addition, miR-382 was demonstrated to inhibit cancer cell growth in osteosarcoma (18) . It was demonstrated in the present study that the miR-382 expression level was decreased in NSCLC tumor tissues and NSCLC cell lines. Furthermore, in vitro experiments indicated that miR-382 mimics greatly inhibited A549 cell growth and migration. These data were consistent with a recent study, which indicated that LMO3 is a well-characterized oncogene and has been reported to be associated with many types of cancer, including NSCLC (10, 11) . Several miRNAs have been reported to directly or indirectly regulate LMO3 to confer anti-cancer effects. For example, low levels of miR-101 have been suggested to lead to hypomethylation of the LMO3 promoter via targeting eEnhancer of zeste homolog 2, EED and DNA (cytosine-5)-methyltransferase 3A, thus contributing to LMO3 overexpression in glioma cells (20) . In the present study, it was demonstrated that LMO3 was negatively associated with miR-382 in tumor tissues from patients with NSCLC.
Notably, overexpression of miR-382 decreased LMO3 mRNA and protein expression in A549 cells. Furthermore, using the luciferase assay, it was indicated that LMO3 was a direct target of miR-382. The present study also demonstrated that miR-382 mimics did not significantly enhance the inhibition of cell proliferation and migration in LMO3-silenced A549 cells. Therefore, these results suggested that miR-382 may be a tumor suppressor in NSCLC, functioning via targeting of LMO3.
In conclusion, the present findings uncovered a tumor suppressor role of miR-382 in NSCLC via directly targeting the oncogene, LMO3. These findings suggest that miR-382 may be a promising diagnostic biomarker for NSCLC. 
